TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 35619221
Drug: Melatonin treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Melatonin treatment (10 mg)
Study: 34424558
Drug: Treatment shampoo
Normalized name: Lice Treatment Shampoo Max
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment shampoo and leave‐on treatment containing functional antioxidants and barrier‐enhancing agents
Study: 32334176
Drug: Clinically indicated
Normalized name: DuoCare Clinical
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clinically indicated replacement group (removal only at end of therapy or in presence of complications)
Study: 32590482
Drug: Bromfenac ophthalmic
Normalized name: bromfenac ophthalmic
DrugBank: Bromfenac (DB00963)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Bromfenac ophthalmic solution 0.09% prescribed 3 times a day for 1 month
Study: 32590482
Drug: Prednisolone acetate
Normalized name: Prednisolone Acetate
DrugBank: Prednisolone acetate (DB15566)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Prednisolone acetate 1% eye suspension prescribed 4 times a day for 1 month
Study: 33557898
Drug: Shi-style cervical
Approvals — FDA: no, EMA: no, PMDA: no
Description: Shi-style cervical manipulation therapy
Study: 33557898
Drug: NSAIDs (traditional
Approvals — FDA: no, EMA: no, PMDA: no
Description: NSAIDs (traditional analgesic drug)
Study: 32655854
Drug: High-dose scopolamine
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose scopolamine
Study: 33331082
Drug: Tocilizumab (8
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tocilizumab (8 mg/kg IV every 4 weeks; 6 doses)
Study: 33370867
Drug: Oseltamivir phosphate
Normalized name: Oseltamivir Phosphate
DrugBank: Oseltamivir (DB00198)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oseltamivir phosphate capsule, 75 mg each time, twice a day for 5 days
Study: 32382987
Drug: Sequencing of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sequencing of novel agents based on RWE data
Study: 33412120
Drug: Nintedanib (150
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nintedanib (150 mg orally twice daily)
Study: 34091874
Drug: Citicoline and
Approvals — FDA: no, EMA: no, PMDA: no
Description: Citicoline and vitamin B12 eye drops (OMK2®, Omikron Italia srl, Italy, one drop thrice daily) for 36 months
Study: 34091874
Drug: Placebo (eye
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (eye drops containing hypromellose 0.3%, one drop thrice daily) for 36 months
Study: 34960030
Drug: 50 mg
Normalized name: talc 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50 mg PXN + 150 mg PLA
Study: 34960030
Drug: 100 mg
Normalized name: urea 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 mg PXN + 100 mg PLA
Study: 34960030
Drug: 200 mg
Normalized name: RNA 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200 mg PXN
Study: 34960030
Drug: 200 mg
Normalized name: RNA 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200 mg PLA
Study: 36104785
Drug: Nebulised unfractionated
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nebulised unfractionated heparin 6 hourly to day 10 while receiving advanced respiratory support
Study: 32727416
Drug: Transoral surgical
Approvals — FDA: no, EMA: no, PMDA: no
Description: Transoral surgical resection with neck dissection followed by risk-adapted adjuvant therapy
Study: 35675742
Drug: Bee-humming respiratory
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bee-humming respiratory training (BHRT), 30 minutes daily for 4 weeks
Study: 33650100
Drug: Carfilzomib (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Carfilzomib (20 mg/m2 on day 1, escalating to 56 mg/m2 maximum) with dexamethasone (10 mg as premedication) during maintenance
Study: 33650100
Drug: Maintenance single-agent
Normalized name: Dental Resources Perio Maintenance Rinse
Approvals — FDA: no, EMA: no, PMDA: no
Description: Maintenance single-agent carfilzomib
Study: 34369682
Drug: Electroacupuncture combined
Normalized name: combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Electroacupuncture combined with ultrasound guided caudal epidural injection
Study: 34369682
Drug: Ultrasound guided
Normalized name: Autologous CD34+ cells isolated from mobilised peripheral blood by positive selection, modified by CRISPR/Cas9 (clustered regularly interspaced short palindromic repeats/CRISPR-associated protein 9) mediated gene editing consisting of a guide RNA (gRNA)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ultrasound guided caudal epidural injection
Study: 33566077
Drug: Regular oral
Normalized name: infant formula,regular ORAL PACKET (EA)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Regular oral hygiene (Control group)
Study: 35634694
Drug: Lemborexant 10
Normalized name: lemborexant 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lemborexant 10 mg plus alcohol (males, 0.7 g/kg; females, 0.6 g/kg)
Study: 35634694
Drug: Lemborexant 10
Normalized name: lemborexant 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lemborexant 10 mg alone
Study: 35634694
Drug: Lemborexant 10
Normalized name: lemborexant 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lemborexant 10 mg plus alcohol
Study: 35634694
Drug: Lemborexant 10
Normalized name: lemborexant 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lemborexant 10 mg alone or with alcohol
Study: 33185932
Drug: Low-dose isotretinoin
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose isotretinoin (0.25 mg/kg/day) and five sessions of pulsed dye laser (PDL)
Study: 33185932
Drug: Standard-dose isotretinoin
Normalized name: Isotretinoin
DrugBank: Isotretinoin (DB00982)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Standard-dose isotretinoin (0.5 mg/kg/day)
Study: 33185932
Drug: ISO group
Normalized name: iso-sulfan blue
Approvals — FDA: no, EMA: no, PMDA: no
Description: ISO group (0.5 mg/kg/day)
Study: 33185932
Drug: ISO/PDL group
Approvals — FDA: no, EMA: no, PMDA: no
Description: ISO/PDL group (0.25 mg/kg/day + PDL)
Study: 35879941
Drug: 10 µg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 µg GBP510 adjuvanted with AS03 (Group 1)
Study: 35879941
Drug: 10 µg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 µg unadjuvanted GBP510 (Group 2)
Study: 35879941
Drug: 25 µg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 25 µg GBP510 adjuvanted with AS03 (Group 3)
Study: 35879941
Drug: 25 µg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 25 µg unadjuvanted GBP510 (Group 4)
Study: 35879941
Drug: 10 µg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 µg or 25 µg GBP510 adjuvanted with AS03
Study: 34001223
Drug: Credelio Plus
Normalized name: Credelio
DrugBank: Lotilaner (DB17992)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Credelio Plus tablets (milbemycin oxime + lotilaner)
Study: 34001223
Drug: Nexgard Spectra®
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nexgard Spectra® tablets (control product)
Study: 34001223
Drug: Credelio Plus
Normalized name: Credelio
DrugBank: Lotilaner (DB17992)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Credelio Plus tablets
Study: 32936874
Drug: Immunonutrient supplement
Approvals — FDA: no, EMA: no, PMDA: no
Description: Immunonutrient supplement (3 sachets/d) enriched with l-arginine and omega-3 fatty acids
Study: 36188425
Drug: Panax notoginseng
Normalized name: PANAX NOTOGINSENG TOP
Approvals — FDA: no, EMA: no, PMDA: no
Description: Panax notoginseng Ejiao suppository
Study: 36188425
Drug: mesalazine suppository
Normalized name: mesalamine Rectal Suppository
Approvals — FDA: no, EMA: no, PMDA: no
Description: mesalazine suppository
Study: 33146324
Drug: Conventional treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional treatment in primary health care
Study: 35787809
Drug: Chamomile oil
Normalized name: chamomile oil
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chamomile oil (1.5 cc applied to lumbar region, three times a day for three weeks)
Study: 33500355
Drug: Androgen deprivation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Androgen deprivation therapy (ADT) combined with orteronel
Study: 33500355
Drug: Androgen deprivation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Androgen deprivation therapy (ADT) combined with bicalutamide
Study: 33409919
Drug: Probiotic and
Normalized name: Florastor Advanced Probiotic And Digestive
Approvals — FDA: no, EMA: no, PMDA: no
Description: Probiotic and selenium co-supplementation (8 × 10^9 CFU/day probiotic plus 200 μg/day selenium)
Study: 35444528
Drug: Non-preparation group
Normalized name: cranberry preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Non-preparation group
Study: 32678530
Drug: Dexamethasone (6
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dexamethasone (6 mg once daily for up to 10 days)
Study: 33399309
Drug: Second-line HIV
Normalized name: Gallus gallus gizzard lining preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Second-line HIV therapy
Study: 33065768
Drug: Medical cannabis
Normalized name: Medical Cannabis
DrugBank: Medical Cannabis (DB14009)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Medical cannabis treatment
Study: 32967912
Drug: Sipuleucel-T (administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sipuleucel-T (administered as three infusions)
Study: 32967912
Drug: Sipuleucel-T (first
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sipuleucel-T (first infusion)
Study: 36258655
Drug: Presented Centered
Approvals — FDA: no, EMA: no, PMDA: no
Description: Presented Centered Therapy (PCT)
Study: 34533246
Drug: Myrtle fruit
Normalized name: Myrtle blueberry fruit
DrugBank: Bilberry (DB14235)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Myrtle fruit syrup with omeprazole
Study: 34533246
Drug: Placebo syrup
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo syrup with omeprazole
Study: 35257230
Drug: Acupressure therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acupressure therapy (8-min acupressure from Zhongwan (CV12), Guanyuan (CV4), and Tianshu (ST25) acupoints once a day for 4 weeks)
Study: 34085769
Drug: YH12852 (0.05-5
Approvals — FDA: no, EMA: no, PMDA: no
Description: YH12852 (0.05-5 mg)
Study: 34085769
Drug: YH12852 (0.05-0.1
Approvals — FDA: no, EMA: no, PMDA: no
Description: YH12852 (0.05-0.1 mg)
Study: 34085769
Drug: YH12852 (doses
Approvals — FDA: no, EMA: no, PMDA: no
Description: YH12852 (doses >0.1 mg extrapolated)
Study: 38869899
Drug: Emotional Awareness
Approvals — FDA: no, EMA: no, PMDA: no
Description: Emotional Awareness and Expression Therapy (EAET)
Study: 37441660
Drug: Oral glibenclamide
Normalized name: glibenclamide
DrugBank: Glyburide (DB01016)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral glibenclamide
Study: 33405051
Drug: G. lucidum
Approvals — FDA: no, EMA: no, PMDA: no
Description: G. lucidum treatment
Study: 33256419
Drug: Pylera® (quadruple
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pylera® (quadruple therapy)
Study: 33256419
Drug: AST-guided triple
Approvals — FDA: no, EMA: no, PMDA: no
Description: AST-guided triple therapy
Study: 33256419
Drug: Both groups
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both groups (Pylera® and AST-guided triple therapy)
Study: 32719981
Drug: Eldecalcitol (ELD)
Normalized name: Decalcitrol
DrugBank: Eldecalcitol (DB05295)
Approvals — FDA: no, EMA: no, PMDA: yes
Description: Eldecalcitol (ELD) 0.75 μg once-a-day for 24 weeks
Study: 32719981
Drug: Alendronate (ALN)
Normalized name: alendronate
DrugBank: Alendronic acid (DB00630)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Alendronate (ALN) 35 mg once-a-week for 24 weeks
Study: 33788465
Drug: Wei's triple
Approvals — FDA: no, EMA: no, PMDA: no
Description: Wei's triple nine needling combined with conventional medication
Study: 33222703
Drug: Inactive control
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inactive control therapy (befriending)
Study: 34144176
Drug: Single-dose HPV
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single-dose HPV vaccination
Study: 34144176
Drug: Two-dose HPV
Approvals — FDA: no, EMA: no, PMDA: no
Description: Two-dose HPV vaccination
Study: 35267477
Drug: Ramucirumab monotherapy
Normalized name: Ramucirumab
DrugBank: Ramucirumab (DB05578)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Ramucirumab monotherapy at 8 mg/kg Q2W
Study: 35267477
Drug: Ramucirumab monotherapy
Normalized name: Ramucirumab
DrugBank: Ramucirumab (DB05578)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Ramucirumab monotherapy at 12 mg/kg Q2W
Study: 35267477
Drug: Ramucirumab monotherapy
Normalized name: Ramucirumab
DrugBank: Ramucirumab (DB05578)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Ramucirumab monotherapy at 6 mg/kg QW
Study: 35267477
Drug: Paclitaxel (80
Approvals — FDA: no, EMA: no, PMDA: no
Description: Paclitaxel (80 mg/m2-D1D8D15) plus ramucirumab (12 mg/kg-Q2W)
Study: 35267477
Drug: Paclitaxel (80
Approvals — FDA: no, EMA: no, PMDA: no
Description: Paclitaxel (80 mg/m2-D1D8D15) plus ramucirumab (8 mg/kg-Q2W)
Study: 33433318
Drug: Ferumoxytol 510
Normalized name: ferumoxytol 510 mg/17 mL (30 mg/mL) INTRAVEN VIAL (ML)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ferumoxytol 510 mg once or twice quarterly
Study: 33433318
Drug: Sodium ferric
Normalized name: Sodium ferric EDTA
DrugBank: Sodium feredetate (DB13381)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sodium ferric gluconate 125 mg weekly
Study: 32151220
Drug: GIK (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: GIK (200 g/L glucose, 66.7 U/L insulin, and 80 mmol/L KCl) administered intravenously at 1 mL/kg per hour 10 minutes before anesthesia and continuously for 12.5 hours
Study: 34177805
Drug: Yoga-based lifestyle
Approvals — FDA: no, EMA: no, PMDA: no
Description: Yoga-based lifestyle modification protocol (YLP) for 9 consecutive days, followed by daily home and weekly supervised practices for 3 months.
Study: 32715401
Drug: TXA (intravenous
Approvals — FDA: no, EMA: no, PMDA: no
Description: TXA (intravenous tranexamic acid)
Study: 35130487
Drug: Multi-dose priming
Normalized name: VIAL ADAPTER MULTI-DOSE ALARIS #2205E
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multi-dose priming regimen (days 1, 8, and 29) with 9 × 10^5 PfSPZ/dose
Study: 35130487
Drug: Multi-dose priming
Normalized name: VIAL ADAPTER MULTI-DOSE ALARIS #2205E
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multi-dose priming regimens (days 1, 3, 5, 7, and 113; days 1, 3, 5, and 7; days 1, 3, 5, 7, and 29)
Study: 35076087
Drug: Naltrexone (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Naltrexone (2 pills)
Study: 35076087
Drug: Naltrexone (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Naltrexone (1 pill)
Study: 35568049
Drug: WEVEE VLP
Normalized name: chikungunya virus antigen, recombinant Senegal strain 37997
Approvals — FDA: no, EMA: no, PMDA: no
Description: WEVEE VLP vaccine (6 μg, 30 μg, or 60 μg) with or without aluminium hydroxide suspension (alum) adjuvant, administered by intramuscular injection at study day 0 and week 8.
Study: 35568049
Drug: 30 μg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 30 μg plus alum group
Study: 35568049
Drug: All doses
Normalized name: All Clear
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: All doses of WEVEE VLP vaccine
Study: 34839481
Drug: Intravenous iron
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous iron (1,000 mg dose of low-molecular weight iron dextran over one hour)
Study: 34839481
Drug: Both groups
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both groups (IV iron and oral iron)
Study: 32200827
Drug: Topical corticosteroids
Normalized name: CORTICOSTEROIDS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical corticosteroids (topical prednisolone phosphate)
Study: 32421159
Drug: Endovascular treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Endovascular treatment (EVT) with standard medical care
Study: 32275032
Drug: Morphine 20
Normalized name: morphine 20 mg/mL oral solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Morphine 20 mg
Study: 36079884
Drug: 6AA (12
Approvals — FDA: no, EMA: no, PMDA: no
Description: 6AA (12 g of non‐essential amino acid formulation orally, 4 g three times a day)
Study: 36079884
Drug: Placebo (equivalent
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (equivalent doses to 6AA)
Study: 33452595
Drug: Exenatide (twice
Approvals — FDA: no, EMA: no, PMDA: no
Description: Exenatide (twice daily for 16 weeks)
Study: 34922061
Drug: Anthocyanins (320
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anthocyanins (320 mg daily for 12 weeks)
Study: 34127089
Drug: Lurasidone monotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lurasidone monotherapy 20-60 mg/d
Study: 34127089
Drug: Lurasidone monotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lurasidone monotherapy 80-120 mg/d
Study: 34127089
Drug: Lurasidone adjunctive
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lurasidone adjunctive therapy 20-120 mg/d + Li/VPA
Study: 34127089
Drug: Lurasidone monotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lurasidone monotherapy (long-term)
Study: 34127089
Drug: Adjunctive lurasidone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adjunctive lurasidone therapy (long-term)
Study: 34127089
Drug: Lurasidone monotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lurasidone monotherapy (pediatric)
Study: 35847029
Drug: Jinzhen Oral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Jinzhen Oral Liquid (JZOL) and Ambroxol Hydrochloride and Clenbuterol Hydrochloride Oral Solution (AHCHOS) placebo
Study: 32963028
Drug: Corticosteroid therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Corticosteroid therapy (dexamethasone)
Study: 36469833
Drug: R-DHAP (rituximab
Approvals — FDA: no, EMA: no, PMDA: no
Description: R-DHAP (rituximab plus dexamethasone, high-dose cytarabine, and cisplatin)
Study: 32718308
Drug: Pharmacotherapy for
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pharmacotherapy for reduction in drinking
Study: 33931884
Drug: Losmapimod 15
Normalized name: Losmapimod
DrugBank: Losmapimod (DB12270)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Losmapimod 15 mg (Part B)
Study: 33931884
Drug: Losmapimod 7.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Losmapimod 7.5 mg (Part B)
Study: 33931884
Drug: Losmapimod 15
Normalized name: Losmapimod
DrugBank: Losmapimod (DB12270)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Losmapimod 15 mg (Part C)
Study: 32381158
Drug: Achieved LDL-C
Approvals — FDA: no, EMA: no, PMDA: no
Description: Achieved LDL-C <20 mg/dl
Study: 32381158
Drug: Achieved LDL-C
Approvals — FDA: no, EMA: no, PMDA: no
Description: Achieved LDL-C ≥100 mg/dl
Study: 35976578
Drug: NOL-guided fentanyl
Normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: NOL-guided fentanyl dosing (NOL)
Study: 33881715
Drug: YYHG high-dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: YYHG high-dose
Study: 33881715
Drug: YYHG low-dose
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: YYHG low-dose
Study: 33881715
Drug: YYHG treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: YYHG treatment
Study: 32207836
Drug: Oral naloxone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral naloxone co-administration with ticagrelor and morphine
Study: 35141806
Drug: L-PRF +
Normalized name: L-377202
DrugBank: L-377202 (DB19022)
Approvals — FDA: no, EMA: no, PMDA: no
Description: L-PRF + DPSC
Study: 32228267
Drug: Risk score
Normalized name: fecal microbiota spores, live Oral Capsule [Vowst]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Risk score based on age >52, WBC >10 × 10^9/L, PLT ≤10 × 10^9/L, LDH >500 U/L
Study: 34324700
Drug: Fremanezumab monthly
Normalized name: Fremanezumab
DrugBank: Fremanezumab (DB14041)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Fremanezumab monthly (675 mg at baseline and 225 mg at weeks 4 and 8)
Study: 34324700
Drug: Fremanezumab quarterly
Normalized name: Fremanezumab
DrugBank: Fremanezumab (DB14041)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Fremanezumab quarterly (675 mg at baseline and placebo at weeks 4 and 8)
Study: 34808749
Drug: Radial shock
Normalized name: methyl salicylate
DrugBank: Methyl salicylate (DB09543)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Radial shock wave therapy (RSWT) in the lateral elbow area plus scapular back area
Study: 34808749
Drug: Radial shock
Normalized name: methyl salicylate
DrugBank: Methyl salicylate (DB09543)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Radial shock wave therapy (RSWT) only in the lateral elbow area
Study: 35172198
Drug: Canagliflozin 100mg
Normalized name: CANAGLIFLOZIN 100MG TAB
DrugBank: Canagliflozin (DB08907)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Canagliflozin 100mg daily
Study: 32275362
Drug: Itopride hydrochloride
Normalized name: Itopride hydrochloride
DrugBank: Itopride (DB04924)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Itopride hydrochloride tablets, 50 mg each time, three times a day for 6 weeks
Study: 34496174
Drug: Iron syrup
Approvals — FDA: no, EMA: no, PMDA: no
Description: Iron syrup
Study: 34496174
Drug: Iron syrup
Approvals — FDA: no, EMA: no, PMDA: no
Description: Iron syrup and multiple micronutrient powders
Study: 34496174
Drug: Iron syrup,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Iron syrup, multiple micronutrient powders, and placebo
Study: 36104745
Drug: Pregabalin (75
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pregabalin (75 mg twice per day) + placebo
Study: 36104745
Drug: Pregabalin (75
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pregabalin (75 mg twice per day) + agomelatine (25 mg per night)
Study: 32029262
Drug: Intranasal dexmedetomidine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intranasal dexmedetomidine 0.5 μg kg‐1
Study: 32029262
Drug: Intranasal dexmedetomidine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intranasal dexmedetomidine 1.0 μg kg‐1
Study: 32029262
Drug: Intranasal dexmedetomidine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intranasal dexmedetomidine 1.5 μg kg‐1
Study: 32029262
Drug: Intranasal dexmedetomidine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intranasal dexmedetomidine 2.0 μg kg‐1
Study: 32029262
Drug: Intranasal dexmedetomidine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intranasal dexmedetomidine (all doses)
Study: 36270561
Drug: Nefecon (16
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nefecon (16 mg/d)
Study: 36343893
Drug: 1 mg
Normalized name: biotin 1 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 mg mocravimod/day
Study: 36343893
Drug: 3 mg
Normalized name: boron 3 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3 mg mocravimod/day
Study: 35306633
Drug: Intensive education
Normalized name: Uricalm Intensive
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intensive education intervention (IG) with repeated, structured multimodal education on correct injection techniques.
Study: 36007870
Drug: Convalescent plasma
Normalized name: Convalescent plasma
DrugBank: COVID-19 convalescent plasma (DB15692)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Convalescent plasma (CP) therapy (300mL)
Study: 33683643
Drug: Energy Healing
Normalized name: Senergy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Energy Healing (EH) therapy with three sessions
Study: 33683643
Drug: Energy Healing
Normalized name: Senergy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Energy Healing (EH) therapy